In a report published Monday, Jefferies reiterated its Buy rating and $32.00 price target on ICON plc ICLR.
Jefferies noted, “ICON has entered into an agreement to buy Cross Country Healthcare's (CCRN, $5.60, NC) clinical trial segment. For the nine-months ending September 30, 2012 the segment generated $51.2M in revenue and a 8.7% contribution margin. In 2011, it generated $64.6M and a 10.1% contribution margin. Approximately 93% of its revenue is derived from clinical trial staffing (~100 recruiters) with the rest from drug safety monitoring and regulatory compliance advisory.”
ICON plc closed on Friday at $29.30.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in